603963 *ST大理药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.241-5.121-4.317-9.4170.690
总资产报酬率 ROA (%)-2.598-4.099-3.364-7.4310.567
投入资产回报率 ROIC (%)-2.888-4.574-3.804-8.6010.660

边际利润分析
销售毛利率 (%)10.64841.59156.33773.21072.697
营业利润率 (%)-43.348-19.520-12.971-23.2112.647
息税前利润/营业总收入 (%)-41.372-18.061-12.171-24.2261.664
净利润/营业总收入 (%)-44.343-22.953-13.375-24.4271.513

收益指标分析
经营活动净收益/利润总额(%)116.942149.674138.25432.937-50.083
价值变动净收益/利润总额(%)-16.584-29.901-33.213-12.461181.403
营业外收支净额/利润总额(%)-0.5981.917-0.9924.296-49.708

偿债能力分析
流动比率 (X)3.4843.7573.9693.8354.217
速动比率 (X)2.7422.9273.6223.5563.458
资产负债率 (%)20.12719.56620.34223.67018.637
带息债务/全部投入资本 (%)11.2479.83310.89811.808--
股东权益/带息债务 (%)786.270912.851815.783739.8992,044.753
股东权益/负债合计 (%)396.853411.099391.595322.476436.556
利息保障倍数 (X)-24.076-9.809-18.106-898.367-15.944

营运能力分析
应收账款周转天数 (天)11.15119.11121.24918.6360.000
存货周转天数 (天)455.621320.861163.351373.5000.000